Pfizer比收入估计数,2025年前景展望提高,并目睹了主要股东活动。 Pfizer beat earnings estimates, raised 2025 outlook, and saw major shareholder activity.

Pfizer Inc.报告,8月5日的第二季度结果强劲,张贴了0.78美元的EPS,超过估计数20美元,产生14.65亿美元的收入,年年增长10.3%。 Pfizer Inc. reported strong second-quarter results on August 5th, posting $0.78 EPS, exceeding estimates by $0.20, and generating $14.65 billion in revenue, a 10.3% year-over-year increase. 该公司将其2025年全年EPS指南提高到2.90至3.10美元,并保持6.9%的股利收益,每年支付1.72美元。 The company raised its full-year 2025 EPS guidance to $2.90–$3.10 and maintains a 6.9% dividend yield with a $1.72 annual payout. 多个公司调整了在公司中的股权,包括Cwm LLC将股权提高6.0%,CCG财富管理LLC将股权提高47.3%,加强家庭和社区LLC将其股权提高871.3%。 Multiple firms adjusted their stakes in the company, including Cwm LLC increasing its position by 6.0%, CCG Wealth Management LLC raising its holdings by 47.3%, and Strengthening Families & Communities LLC boosting its stake by 871.3%. JFS财富顾问有限公司将其持有的股份减少了676股。 JFS Wealth Advisors LLC reduced its holding by 676 shares. 股票有一致的“等待”评分,目标价格为28.35美元。 The stock has a consensus "Hold" rating and a target price of $28.35.